incagn01949
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02923349)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- incagn01949
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04387071 | Phase 1/Phase 2 (Phase 2) | May 15, 2020 | National Cancer Institute (NCI), University of Southern California |
| NCT03241173 | Phase 1/Phase 2 (Phase 2) | Oct 2, 2017 | Incyte |
| NCT02923349 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | Incyte |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 2 | 2 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1